- Imugene Limited will be giving an oral presentation of an abstract about the overall survival results from its HER-Vaxx HERIZON study at the ESMO Asia Congress 2022
- The event will be held from 2-4 December in Singapore
- Principal investigator Marina Maglakelidze will present the abstract during a session on gastrointestinal tumours on 4 December 2022, 1:40pm (SGT)
Imugene Limited (ASX:IMU), a renowned clinical-stage immuno-oncology company, has got a major opportunity to present an abstract about the overall survival results from its HER-Vaxx HERIZON study at the ESMO Asia Congress 2022.
The ESMO Asia Congress has accepted the company’s abstract for an oral presentation at the event, scheduled to be held from 2-4 December in Singapore. At the annual meet, cancer professionals from Asia and other parts of the world come together to present and discuss the most recent scientific and clinical developments in the field of oncology.
The title for the oral presentation and abstract (no. 74MO) is 'HERIZON Overall Survival Results: A Study of IMU-131, a HER2 Targeting Peptide Vaccine, Plus Standard of Care Chemotherapy in Patients with HER2 Overexpressing Metastatic or Advanced Gastric/GEJ Cancer'. The presentation will be a part of a session to be conducted on gastrointestinal tumours on 4 December 2022, 1:40pm (SGT), by principal investigator Marina Maglakelidze.
An overview of HERIZON study
The HERIZON study was a Phase 2 clinical trial of Imugene's HER-Vaxx technology in Her-2/Neu overexpressing advanced/metastatic gastric/GEJ cancer. HER-Vaxx is a B-cell activating cancer immunotherapy, developed for treating tumours which overexpress the HER-2/neu receptor, like lung, gastric, breast, pancreatic, and ovarian cancers. The immunotherapy is built using multiple B cell epitopes derived from the extracellular domain of HER2/neu.
Imugene’s shares were spotted trading 3.947% higher at AU$0.197 (as at 02:42 PM AEDT) on 7 October 2022.